NovaBridge Biosciences (NBP) a un PER historique négatif de -24.4, ce qui signifie que l'entreprise est actuellement non rentable sur la base des douze derniers mois (TTM). Le rendement bénéficiaire historique est de -4.10%.
Critères prouvés par cette page:
Score Global SharesGrow : 66/100 avec 3/7 critères réussis.
| Year | P/E (TTM) | Ratio PEG | Ratio P/B | Ratio P/S | Rendement du Dividende |
|---|---|---|---|---|---|
| 2017 | -15.9 | 0.00 | -15.78 | 409.39 | - |
| 2018 | -12.4 | -0.36 | -5.23 | 92.96 | - |
| 2019 | -3.4 | -0.01 | -2.49 | 168.74 | 0.10% |
| 2020 | 44.6 | -0.34 | 3.73 | 13.61 | - |
| 2021 | -9.8 | 0.02 | 4.98 | 259.67 | - |
| 2022 | -0.9 | 0.90 | 0.79 | -222.39 | - |
| 2023 | -0.8 | 0.02 | 0.65 | 250.09 | - |
| 2024 | -0.4 | 0.01 | 0.34 | 0.00 | - |
| Year | EPS (Dilué) | Chiffre d'Affaires | Résultat Net | Marge Nette |
|---|---|---|---|---|
| 2017 | $-5.13 | $11.56M | $-298.24M | -2580.8% |
| 2018 | $-6.92 | $53.78M | $-402.83M | -749% |
| 2019 | $-25.53 | $30M | $-1.49B | -4950% |
| 2020 | $6.90 | $1.54B | $470.92M | 30.5% |
| 2021 | $-30.68 | $88.03M | $-2.33B | -2648.7% |
| 2022 | $-30.38 | $-10.7M | $-2.51B | - |
| 2023 | $-17.62 | $4.49M | $-1.47B | -32674% |
| 2024 | $-4.46 | $0.00 | $-162.26M | - |
| Year | EPS (Moy.) | Fourchette EPS | CA (Moy.) | Fourchette CA | Analystes |
|---|---|---|---|---|---|
| 2026 | $-1.00 | $-1.50 – $-0.49 | $0.00 | $0.00 – $0.00 | 2 |
| 2027 | $-1.69 | $-1.74 – $-1.62 | $0.00 | $0.00 – $0.00 | 2 |
| 2028 | $-2.07 | $-2.73 – $-1.34 | $106.54M | $106.54M – $106.54M | 3 |
| 2029 | $-2.14 | $-2.14 – $-2.14 | $167.95M | $167.95M – $167.95M | 1 |
| 2030 | $0.41 | $0.41 – $0.41 | $502.62M | $502.62M – $502.62M | 1 |
